Intellectual Property India Publishes Patent Application for 'Rna Inhibitor For Inhibiting Lpa Gene Expression And Use Thereof' Filed by Kylonova (XIAMEN) Biopharma Co. Ltd.

MUMBAI, India, May 30 -- Intellectual Property India has published a patent application (202517044792 A) filed by Kylonova (XIAMEN) Biopharma Co. Ltd., Fujian, China, on May 8, for 'rna inhibitor for inhibiting lpa gene expression and use thereof.'

Inventor(s) include Cui Kunyuan; and Lu Xueqin.

The application for the patent was published on May 30, under issue no. 22/2025.

According to the abstract released by the Intellectual Property India: "Provided is an RNA inhibitor for inhibiting LPA gene expression or a pharmaceutically acceptable salt thereof. The RNA inhibitor is formed by base pairing of a sense strand and an antisense strand having a chain length of 15 30 and the chain length is preferably 19 23; at least 85% of bases of the sense strand and the antisense strand are complementary to each other; OH at position 2 of some or all of nucleotide glycosyls of the sense strand and/or the antisense strand is substituted with fluorine or methoxy; and phosphate bonds among three adjacent nucleotides of at least one of terminuses of the sense strand and/or antisense strand can be thioated. The structure of the RNA inhibitor may also contain vector structures 5MVIP and 3MVIP. The RNA inhibitor provided in the present application interferes with the translation template function of the LPA mRNA continuously and efficiently inhibits LPA gene expression and can be used for treating and/or preventing diseases related to the horizontal increase of LP(a)."

The patent application was internationally filed on Oct. 23, 2023, under International application No.PCT/CN2023/125861.

Disclaimer: Curated by HT Syndication.